Pulmonary hypertension is a serious disease with a poor prognosis. Pulmonary hypertension is defined by a mean pulmonary arterial pressure over 25 mm Hg at rest or over 30 mm Hg during activity. According to the recent WHO classification from 2003 pulmonary hypertension can be categorized as pulmonary arterial hypertension, pulmonary venous hypertension, hypoxic pulmonary hypertension, chronic ...

The inherited hemoglobin disorders sickle cell disease and thalassemia are the most common monogenetic disorders worldwide. Pulmonary hypertension is one of the leading causes of morbidity and mortality in adult patients with sickle cell disease and thalassemia, and hemolytic disorders are potentially among the most common causes of pulmonary hypertension. The pathogenesis of pulmonary hyperten...

BACKGROUND Chloride intracellular channel 4 (CLIC4) is highly expressed in the endothelium of remodeled pulmonary vessels and plexiform lesions of patients with pulmonary arterial hypertension. CLIC4 regulates vasculogenesis through endothelial tube formation. Aberrant CLIC4 expression may contribute to the vascular pathology of pulmonary arterial hypertension. METHODS AND RESULTS CLIC4 prote...

Pulmonary hypertension has been observed to be elevated among end-stage renal disease and patients who are on dialysis. Several investigations, have demonstrated that, pulmonary hypertension in end-stage kidney failure patients is related to expressively enhanced mortality and morbidity. Pulmonary hypertension represents a group of comparatively erratic illnesses that causes different pulmonary...

We describe a 54-year-old woman with isolated pulmonary arterial hypertension accompanied by hyperthyroidism due to Graves' disease. Her pulmonary artery hypertension resolved spontaneously after restoration of euthyroidism. This case suggests that hyperthyroidism should be considered a reversible cause of pulmonary arterial hypertension.

HE PATHOGENESIS of the syndrome "primary pulmonary arterial hyper-tension has been the subject of inereasing interest in recent years.12 The syndrome is characterized by pulmonary arterial hypertension in the absence of significant primary pulmonary parenchymatous disease or primary cardiac disorder. The hypertension has usually been attributed to pulmonary vascular lesions, which increase the ...

conclusions we observed acceptable results regarding both efficacy and safety with 62.5 mg of bosentan, twice daily in this group of patients. further clinical trials investigating pah with lower dosages of bosentan may be warranted. results no adverse drug reaction was observed during the follow-up. clinical worsening occurred in six (14%) patients, at least one year after treatment, two of th...

BACKGROUND Serotonin promotes pulmonary arterial vasoconstriction and pulmonary arterial smooth muscle cell proliferation, thereby having the potential to increase pulmonary arterial blood pressure. Although serotonin reuptake inhibitors (SRIs) might inhibit further deterioration in patients with manifest pulmonary arterial hypertension, they may induce pulmonary hypertension in healthy newborn...

Integration of omics with clinical data through machine learning is the future personalised and precision medicine in systemic sclerosis-associated pulmonary arterial hypertensionhttps://bit.ly/3jsyBoV